IceCure Medical Ltd. Ordinary Shares (ICCM)

FairStock Score: 47/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Graham-style investor, I see IceCure as a commercial-stage medical-device firm with a tiny revenue base and no durable moat I can identify from the data. In the latest reported quarter (2026-Q2), revenue was $907,000, while net income was -$4.5 million, a -496.25% margin. The stated revenue growth of 25.66% is encouraging, but profit growth of -19.12% and trailing free cash flow of -$15.9 million show the business consumes far more cash than it generates. The balance sheet has low debt—D/E 0.01—but that is cold comfort when the Altman Z-Score is -7.77 and the Piotroski F-Score is 4/9. At the 2026-10-13 close of $1.10, FairStock calculations show P/B of 0.32, a $24.1 million market cap, ROE of -228.31%, ROCE of -73.88%, and FCF yield of -66.2%. The stock trades below accounting book value, but book value is being eroded by losses. A low P/B can be a value trap when future cash flows are negative. Beta of 0.45 and the 52-week range of $0.22 to $9.54 suggest sentiment is unstable. IceCure needs to prove it can scale sales and reach positive cash flow. Until then, it is a speculative story, not a Graham bargain. The 47/100 FairStock Score reflects the mixed evidence.

In plain English: IceCure Medical makes medical devices that use cold to destroy tumors. Sales are growing, but the company is still losing much more money than it brings in and burns cash. The share price looks low compared with its stated accounting value, but the business itself remains weak, so cheapness is not the same as safety.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer